Meeting Thu, 06/17/2021 - 12:00 Drug Prior Authorization Committee Meeting Information

Date
Media
New Drugs Edits June 2021
Edit Implementation Schedule June 2021
PDL Recommendations June 2021
PDL Announcements June 2021
Conduent Reports June 2021
CyberAccess User Statistics June 2021
Agenda
DPA Agenda June 2021
Minutes
DPA Minutes June 2021
Criteria
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Amylin Analogs June 2021
Antibiotic Vaginal June 2021
Bile Salt Agents June 2021
Cephalosporin Agents June 2021
Electrolyte Depleting Agents Phosphate Lowering June 2021
Electrolyte Depleting Agents Potassium Lowering June 2021
Fluoroquinolone Agents Oral June 2021
Insulin Mixed June 2021
Insulin Non Analogs June 2021
Penicillin Agents June 2021
Sulfonylurea Agents Second Generation June 2021
Targeted Immune Modulators IL6 Receptor Inhibitors June 2021
Thrombocytopenia Agents June 2021
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Alpha Glucosidase Inhibitors June 2021
Antibiotics GI Oral June 2021
Antibiotics Mupirocin Topical June 2021
Antihyperuricemic Agents June 2021
Benign Prostatic Hyperplasia Agents June 2021
Biguanides June 2021
Bone Ossification Agents June 2021
Colony Stimulating Factors June 2021
Cryopyrin Associated Periodic Syndrome June 2021
DPPIV Inhibitor June 2021
Erythropoiesis Stimulating Agents June 2021
GLP 1 Agonists June 2021
Growth Hormone Agents Somatropin June 2021
Growth Hormone Releasing Factors Select Agents June 2021
Insulin Long Acting June 2021
Insulin Rapid Acting June 2021
LHRH GnRH Agents Non Oral June 2021
Macrolide Agents June 2021
Meglitinide Agents June 2021
Methotrexate Agents June 2021
Multiple Sclerosis Agents Injectable June 2021
Multiple Sclerosis Agents Oral June 2021
SGLT2 Inhibitors June 2021
Targeted Immune Modulators IL17 June 2021
Targeted Immune Modulators IL23 IL12 inhibitors June 2021
Targeted Immune Modulators JAK Inhibitors June 2021
Targeted Immune Modulators Select Agents June 2021
Targeted Immune Modulators TNF Inhibitors June 2021
Tetracycline Agents June 2021
Thiazolidinediones June 2021
Urinary Tract Antispasmodics June 2021
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Ampyra June 2021
Elagolix June 2021
Gamifant June 2021
Koselugo June 2021
Luxturna June 2021
Oxervate June 2021
Reblozyl June 2021
Synagis June 2021
Tepezza June 2021
Tolvaptan June 2021
Zometa June 2021
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
CAR T Cell June 2021
Crysvita June 2021
DMD June 2021
Entresto June 2021
Extended Supply June 2021
HBV Nucleotide Analog June 2021
Imcivree June 2021
Iron Injectable June 2021
Nulibry June 2021
Oxazolidinone June 2021
Palynziq June 2021
PTH and Other Agents June 2021
Verquvo June 2021
Zokinvy June 2021
Page
Drug Prior Authorization Committee Meeting Information